President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.» Read More
Stocks declined Tuesday amid concerns about interest rates and a slide in consumer confidence. Merck dragged on the Dow industrials after the FDA rejected a key cholesterol drug.
Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.
U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.
Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.
It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.
Earnings Season shifted into high gear, both corporate results and economic statistics were all over the proverbial map, and investors and traders found opportunities in some unlikely places.
The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.
Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...
This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...
The iPhone was big. This could be even bigger, Cramer says.
Merck and Eli Lilly reported earnings today, and CNBC asked the pharmaceutical companies’ chief executives and an analyst to discuss the results and the sector as a whole.
I usually cover pharma earnings from my desk at CNBC HQ in Englewood Cliffs, NJ. But because Merck made a rare offer to interview its Chairman and CEO Dick Clark exclusively this morning I'm out at Merck's idyllic HQ campus in central NJ.
Stocks close mixed as quarterly results from Bank of America and National City fueled worries about bank earnings, while energy and tech gained.
Merck's revenues were light, but market reaction was positive. Eli Lilly's earnings were up sharply, but still disappointed the Street. So how does an investor play the results?
Stocks started the week lower, hurt by more uncertainty in the banking industry and earnings report that left investors wary after coming off a strong rally last week.
Monday has not been a great day for bank earnings. Last Monday it was Wachovia that disappointed, today futures dropped at 7 am ET as Bank of America came short of expectations.
Merck said first-quarter profit rose on gains from a deal with longtime partner AstraZeneca, although the company's sales rose only 1 percent as negative results of a clinical trial slowed growth of its Vytorin and Zetia cholesterol drugs.
Stock index futures pointed to a lower start for the week as the first wave in a big week of earnings reports left investors wary.
Whenever the stock market rushes full speed ahead, it is hard not to look for the big let-down. That could be the case in the week ahead... Major earnings reports, housing data, annual shareholder meetings, and Tuesday's Pennsylvania presidential primaries are what traders will be watching to see if the trend continues.
Signs of renewed confidence in the U.S. financial system could support the dollar next week, provided March's housing reports do not revive chances of a steep interest rate cut.